Monday, June 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

European Union’s new COVID-19 surge highlights vaccination missteps

The European Union is rich, scientifically advanced and endowed with excellent health-care and welfare systems and a political consensus tilted strongly towards looking after its citizens. Yet during the pandemic it has stumbled.

In the brutal and blunt league table of fatalities, the EU as a whole has done less badly than Britain or America, with 138 recorded deaths per 100,000, compared with 187 and 166 respectively—though Hungary, the Czech Republic and Belgium have all fared worse than either.

However, it is in the grip of a vicious surge fuelled by a deadly variant. That underlines the peril of Europe’s low rate of vaccination.

Source: The Economist

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!